The financials
Alnylam Pharmaceuticals, Inc. by the numbers
Alnylam Pharmaceuticals, Inc. (ALNY) reported revenue of $2.46B in H1 2026 (quarter ended June 30, 2026), up 314% from the same quarter a year earlier. That came with a gross margin of 79% and net income of $370M (15% of revenue). For the full year FY2025, revenue was $3.71B (+65% year on year) and net income $314M. Its largest product in 2026-Q1 was Amvuttra at $703M, 63% of the disclosed total, just ahead of Rare at 11%.
| Income statement | H1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $2.46B | $594M | +314% |
| Gross profit | $1.95B | $524M | +273% |
| Operating income | $500M | $18M | +2666% |
| Net income | $370M | −$18M | to a profit |
| Diluted EPS | $2.71 | −$0.14 | to a profit |
| Product | Revenue | Share |
|---|---|---|
| Amvuttra | $703M | 63% |
| Rare | $126M | 11% |
| Collaborations | $82M | 7.3% |
| GIVLAARI | $49M | 4.4% |
| Royalty | $49M | 4.4% |
| Other License Programs | $40M | 3.6% |
| Development Services Obligation | $34M | 3.1% |
| OXLUMO | $17M | 1.5% |
| ONPATTRO | $10M | 0.9% |
| Research Services Obligation | $6.6M | 0.6% |
| Product And Service Other | $1.2M | 0.1% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q1 2026Total $1.12B (-25%)
Amvuttra grew +255% year on yearRegeneron Technology Transfer Obligation -100% year on year
Segment Latestquarter on quarteryear on year
- Amvuttra$702.6M$702.6MQoQ +32%year on year +255%+32%+255%
- Rare$125.7M$125.7MQoQ -0.78%year on year +15%-0.78%+15%
- Collaborations$82.1M$82.1MQoQ -77%year on year -17%-77%-17%
- GIVLAARI$49.1M$49.1MQoQ -2.6%year on year +12%-2.6%+12%
- Royalty$49.0M$49.0MQoQ +6.0%year on year +85%+6.0%+85%
- Other License Programs$39.7M$39.7MQoQ +297%year on year +198%+297%+198%
- Development Services Obligation$34.4M$34.4MQoQ +37%year on year +117%+37%+117%
- OXLUMO$17.0M$17.0MQoQ -18%year on year +20%-18%+20%
- ONPATTRO$10.2M$10.2MQoQ -19%year on year -35%-19%-35%
- Research Services Obligation$6.6M$6.6MQoQ -47%year on year -52%-47%-52%
- Product And Service Other$1.2M$1.2MQoQ -14%year on year +1.6%-14%+1.6%
- C5 Co Co Obligation--QoQ -year on year ---
- C5 License Obligation$0.00$0.00QoQ -year on year -100%--100%
- C5 Monotherapy Obligation--QoQ -year on year ---
- License Obligation--QoQ -year on year ---
- Regeneron Technology Transfer Obligation$0.00$0.00QoQ -year on year -100%--100%
- Technology Transfer Obligation--QoQ -year on year ---
Biotechnology
Ranks #57 of 145 by Smart Score